Material Event (Form 8-K)

Item 8.01 Other Events.

As previously disclosed, on September 4, 2025, Artelo Biosciences, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with R. F. Lafferty & Co., Inc., the sole book-running manager and underwriter (the "Underwriter"), relating to an underwritten offering (the "Offering") of (i) 640,924 shares (the "Shares") of common stock, par value $0.001 per share, of the Company (the "Common Stock"), at a price to the public of $4.40 per share (the "Share Purchase Price"), and (ii) pre-funded warrants to purchase up to 40,894 shares of Common Stock at an exercise price of $0.001 per share (the "Pre-funded Warrants," and, together with the Shares, the "Securities"), at a price to the public of $4.399 per Pre-funded Warrant, for aggregate gross proceeds of approximately $3,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering was closed on September 5, 2025. The Company delivered the Securities to the Underwriter on the same day.

Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 45-day option (the "Over-allotment Option") to purchase up to an additional 102,272 shares of Common Stock at the Share Purchase Price per share, less the underwriting discounts to cover over-allotments, if any.

On September 11, 2025, the Underwriter exercised the Over-allotment Option in part to purchase an additional 57,914 shares of Common Stock, generating gross proceeds to the Company of approximately $0.25 million and net proceeds of approximately $0.24 million. The closing of this exercise of the Over-allotment Option took place on the same day.